188 related articles for article (PubMed ID: 32397338)
1. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
[TBL] [Abstract][Full Text] [Related]
4. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
7. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
[TBL] [Abstract][Full Text] [Related]
9. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of a heterodinucleotide of BVDU and gemcitabine.
Cappellacci L; Franchetti P; Vita P; Petrelli R; Grifantini M
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):460-8. PubMed ID: 18569785
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies.
Jin Y; Lian Y; Du L; Wang S; Su C; Gao C
Int J Pharm; 2012 Jul; 430(1-2):276-81. PubMed ID: 22486963
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
14. Preparation of intravenous injection nanoformulation via co-assemble between cholesterylated gemcitabine and cholesterylated mPEG: enhanced cellular uptake and intracellular drug controlled release.
Xu Y; Zhong X; Zhang X; Lv W; Yu J; Xiao Y; Liu S; Huang J
J Microencapsul; 2017 Mar; 34(2):185-194. PubMed ID: 28378597
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
[TBL] [Abstract][Full Text] [Related]
16. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.
Limmer S; Hahn J; Schmidt R; Wachholz K; Zengerle A; Lechner K; Eibl H; Issels RD; Hossann M; Lindner LH
Pharm Res; 2014 Sep; 31(9):2276-86. PubMed ID: 24599802
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
20. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]